Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Unknown 4Recruiting 4Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 11Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 7Head and Neck Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasms 5Colorectal Neoplasms 5Advanced Solid Tumor 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Transitional Cell 4Carcinoma, Renal Cell 4Solid Tumor 3Small Cell Lung Carcinoma 3Recurrence 3Rectal Neoplasms 3Nasopharyngeal Neoplasms 3Turcot syndrome 2Sarcoma 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Microsatellite Stable Metastatic Colorectal Cancer 2Locally Advanced Rectal Cancer 2Liposarcoma 2Laryngeal Neoplasms 2Gestational Trophoblastic Disease 2Esophageal Neoplasms 2

Interventions

pembrolizumab 21enfortumab vedotin 13Gemcitabine 12Nivolumab 8Cisplatin 8Carboplatin 8Magnetic Resonance Spectroscopy 6Specimen Handling 5Docetaxel 5toripalimab 4sacituzumab govitecan 4Paclitaxel 4Ipilimumab 4atezolizumab 3Mitomycin 3Fluorouracil 3disitamab vedotin 2cabozantinib 2avelumab 2Radiosurgery 2Platinum 2Injections 2Immunotherapy 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Biopsy 2zanidatamab 1tremelimumab 1tamibarotene 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Transitional Cell × toripalimab × Clear all
NCT07314723 2026-01-02

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT06823427 2025-03-21

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2 Recruiting
60 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT06592326 2024-09-19

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 3 Recruiting
460 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05302284 2023-12-18

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

RemeGen Co., Ltd.

Phase 3 Recruiting
452 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡